IL-17, IL-23, and p73 expression in cutaneous melanoma: a pilot study

Melanoma Research
Giulia GanzettiAnnamaria Offidani

Abstract

The incidence of cutaneous malignant melanoma is increasing worldwide, resulting in the demand for clinically useful prognostic biomarkers, especially for invasive and metastatic disease. We studied the immunohistochemical expression of interleukin-17 (IL-17), IL-23, and p73 in 35 malignant melanomas and compared them with benign melanocytic nevi and Spitz nevi, correlating them with clinical-pathological variables. A higher and statistically significant difference (P<0.05) in the intensity and percentage of stained cells of IL-17 and IL-23 was found in the melanoma group than in ordinary benign nevi that did not correlate with Breslow thickness nor Clark level. Moreover, p73 staining and percentage of stained cells was significantly higher (P<0.05) in all the melanomas studied, with a peculiar cytoplasmatic distribution. Our findings could suggest a possible IL-17, IL-23, and p73 involvement in cutaneous melanomas with a hypothetical impact on melanoma invasiveness.

References

Feb 1, 1984·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J L CordellD Y Mason
Jul 9, 1999·Immunology Letters·F PagesW H Fridman
Apr 13, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mirko MarabeseMassimo Broggini
Jul 29, 2008·Biochemical and Biophysical Research Communications·Bin ZhangGuoen Fang
Jul 1, 2009·The Journal of Experimental Medicine·Lin WangHua Yu
Dec 5, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claus GarbeAlexander Eggermont
Feb 2, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayE Steliarova-Foucher
Mar 2, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ilona KryczekWeiping Zou
Aug 29, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Maio
Mar 29, 2014·Cancer Investigation·Paul ZarogoulidisKonstantinos Zarogoulidis
May 3, 2014·Acta Dermato-venereologica·Giulia GanzettiAnnamaria Offidani
Aug 3, 2014·Cold Spring Harbor Perspectives in Medicine·Vladimir A Botchkarev, Elsa R Flores

❮ Previous
Next ❯

Citations

Dec 13, 2017·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·N RodríguezG Domínguez
Jul 19, 2017·Cold Spring Harbor Perspectives in Biology·Juming YanMichele W L Teng
Feb 9, 2018·Melanoma Research·Giulia GanzettiMonica Emanuelli
Oct 31, 2019·International Journal of Dermatology·Nicoletta BernardiniConcetta Potenza
Feb 5, 2021·Dermatopathology·Oriana SimonettiAnnamaria Offidani
Dec 2, 2020·The Journal of Allergy and Clinical Immunology·Raquel Castillo-GonzálezFrancisco Sánchez-Madrid

❮ Previous
Next ❯

Software Mentioned

GraphPad
QuickCalcs
ImageScope
GraphPad Prism

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.